On Wednesday in Dallas, just one day after the initiative was launched by the National Institutes of Health (NIH), Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.Read more
A new analysis by University of Chicago Medicine faculty, staff and collaborators around the world found remdesivir appears to be equally beneficial to patients regardless of race, supporting the need for early intervention and aggressive care for all patients in the fight against COVID-19.Read more
A Nature study authored by a global team of scientists and led by Sumit Chanda, Ph.D., professor at Sanford Burnham Prebys Medical Discovery Institute, has identified 21 existing drugs that stop the replication of SARS-CoV-2, the virus that causes COVID-19.Read more
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
Penn State Health Milton S. Hershey Medical Center has enrolled its first patients in the continuation of a clinical trial using the investigational antiviral drug remdesivir for treatment of COVID-19.Read more
Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.Read more
Necessity being the mother of invention, Houston Methodist clinicians, researchers and staff have collaborated on a number of clinical device and research innovations in response to COVID-19. Houston Methodist Academic Institute leadership has continually emphasized translational research in new technologies.Read more
Baylor Scott & White Research Institute, the research arm of Baylor Scott & White Health, is bringing clinical trials online at an unprecedented pace in response to COVID-19. A COVID-19 therapeutic task force of more than 20 multidisciplinary researchers positioned across the state of Texas has been putting their expertise in infectious disease, cardiology, immunology, molecular biology, and other specialties together to explore research opportunities for experimental prevention and treatment options and to develop investigator-initiated studies.Read more
In a small group of patients hospitalized with severe complications of COVID-19 and treated with the experimental antiviral drug remdesivir, clinical improvement was observed in 68% of patients treated, according to an analysis co-authored by Jonathan Grein, MD, director of Hospital Epidemiology at Cedars-Sinai.Read more
UCLA Health is one of 75 sites around the globe participating in a clinical trial sponsored by the National Institutes of Health to test the effectiveness of a candidate anti-viral drug against COVID-19.Read more